Stock ARVN ARVINAS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Arvinas, Inc.

Equities

ARVN

US04335A1051

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
31.9 USD -1.45% Intraday chart for Arvinas, Inc. -8.60% -22.50%
04-24 Arvinas, Inc. Appoints Randy Teel as Chief Business Officer CI
04-15 H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating MT

Evolution of the average Target Price on Arvinas, Inc.

Price target over the last 5 years

History of analyst recommendation changes

05e3faa190382cb6f7bc4eae36.OUxNVxIeHV3G0hxnytpsemTy9DyoQK7OVEQwg9OiuZU.TycdYFx8eg2npVQpsJlVPwGAvkbBKvilY31TtJDwiucAGX4jZGR1KIifaw~c842b41bbbe53b7a1dcad94790763bf4

Analyst Recommendations on Arvinas, Inc.

H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating MT
HC Wainwright Adjusts Arvinas' Price Target to $87 From $90, Keeps Buy Rating MT
Wedbush Adjusts Arvinas' Price Target to $57 From $59, Keeps Outperform Rating MT
Barclays Adjusts Arvinas' Price Target to $60 From $26, Maintains Overweight Rating MT
BMO Capital Adjusts Arvinas' Price Target to $90 From $89, Maintains Outperform Rating MT
Oppenheimer Adjusts Arvinas Price Target to $80 From $95, Maintains Outperform Rating MT
Wedbush Raises Arvinas' PT to $59 From $33, Sees 'Strong' Set Up in 2024; Keeps Outperform Rating MT
Citigroup Downgrades Arvinas to Neutral From Buy, Adjusts Price Target to $55 From $36 MT
Wells Fargo Upgrades Arvinas to Overweight From Equalweight, Price Target to $63 MT
Jefferies Upgrades Arvinas to Buy From Hold, Raises Price Target to $40 From $32 MT
Wedbush Raises Arvinas' PT to $33 From $24, Says Vepdegestrant Combined With Palbociclib for Potential Breast Cancer Treatment Continues to Impress; Maintains Outperform Rating MT
Guggenheim Upgrades Arvinas to Buy From Neutral, Price Target is $40 MT
Morgan Stanley Adjusts Price Target on Arvinas to $20 From $32, Reiterates Equalweight Rating MT
Citigroup Adjusts Arvinas' Price Target to $36 From $72, Maintains Buy Rating MT
Barclays Adjusts Price Target on Arvinas to $26 From $39, Keeps Overweight Rating MT
Wedbush Upgrades Arvinas to Outperform From Neutral After Recent Sell-Off, Notes Plans to De-Prioritize Bavdegalutamide in Favor of ARV-766; Adjusts PT to $24 From $27 MT
Citigroup Adjusts Arvinas Price Target to $72 From $77, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Arvinas to $32 From $35, Maintains Equal-Weight Rating MT
Barclays Lowers Price Target on Arvinas to $39 From $70, Maintains Overweight Rating MT
UBS Adjusts Arvinas Price Target to $90 From $151, Maintains Buy Rating MT
Morgan Stanley Trims Price Target on Arvinas to $35 From $38, Maintains Equalweight Rating MT
Wedbush Lowers Arvinas' PT to $27 From $30, Says Continues to See Lack of Needle Moving Events; Keeps Neutral Rating MT
Stifel Cuts Price Target on Arvinas to $72 From $75, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Arvinas to $36 From $57, Maintains Equal-Weight Rating MT
Credit Suisse Lowers Arvinas' Price Target to $61 From $81, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
32.37 USD
Average target price
69.89 USD
Spread / Average Target
+115.91%
High Price Target
110 USD
Spread / Highest target
+239.82%
Low Price Target
38 USD
Spread / Lowest Target
+17.39%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Arvinas, Inc.

HC Wainwright
Wedbush
Barclays
BMO Capital
Oppenheimer
Citigroup
Wells Fargo Securities
Jefferies & Co.
Guggenheim
Morgan Stanley
UBS
Stifel Nicolaus
Credit Suisse
Cantor Fitzgerald
Truist Securities
Piper Sandler
SVB Securities LLC
Goldman Sachs
Cowen
SVB Leerink
BofA Securities
Roth Capital Partners

Ratings for Arvinas, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ARVN Stock
  4. Consensus Arvinas, Inc.